Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Lowe

Showing results (491-500 of 520) with videos related to

Pageof 52
Sort By:
Plos One|October 16, 2018
An approved in vitro approach to preclinical safety and efficacy evaluation of engineered T cell receptor anti-CD3 bispecific (ImmTAC) moleculesJane Harper, Katherine J Adams, Giovanna Bossi, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|November 18, 2011
Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitorPatrick C May, Robert A Dean, Stephen L Lowe, et al.
JMIR Research Protocols|October 4, 2019
VEROnA Protocol: A Pilot, Open-Label, Single-Arm, Phase 0, Window-of-Opportunity Study of Vandetanib-Eluting Radiopaque Embolic Beads (BTG-002814) in Patients With Resectable Liver MalignanciesLaura Beaton, Henry F J Tregidgo, Sami A Znati, et al.
Journal of Vascular and Interventional Radiology : JVIR|May 8, 2022
Phase 0 Study of Vandetanib-Eluting Radiopaque Embolics as a Preoperative Embolization Treatment in Patients with Resectable Liver MalignanciesLaura Beaton, Henry F J Tregidgo, Sami A Znati, et al.
Plos One|March 28, 2013
CNV analysis in Tourette syndrome implicates large genomic rearrangements in COL8A1 and NRXN1Abhishek Nag, Elena G Bochukova, Barbara Kremeyer, et al.
Journal of Medicinal Chemistry|June 3, 2021
Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE InhibitorDavid L McKinzie, Leonard L Winneroski, Steven J Green, et al.
Genetic Epidemiology|February 11, 2011
Gene-environment interplay in common complex diseases: forging an integrative model—recommendations from an NIH workshopEbony B Bookman, Kimberly McAllister, Elizabeth Gillanders, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|January 23, 2015
The potent BACE1 inhibitor LY2886721 elicits robust central Aβ pharmacodynamic responses in mice, dogs, and humansPatrick C May, Brian A Willis, Stephen L Lowe, et al.
BMC Medicine|January 28, 2024
Integrating multiple lines of evidence to assess the effects of maternal BMI on pregnancy and perinatal outcomesMaria Carolina Borges, Gemma L Clayton, Rachel M Freathy, et al.
Human Molecular Genetics|September 8, 2012
Genetic variation in the 15q25 nicotinic acetylcholine receptor gene cluster (CHRNA5-CHRNA3-CHRNB4) interacts with maternal self-reported smoking status during pregnancy to influence birth weightJessica Tyrrell, Ville Huikari, Jennifer T Christie, et al.
Pageof 52

Showing results (491-500 of 520) with videos related to

Sort By:
Pageof 52
Plos One|October 16, 2018
An approved in vitro approach to preclinical safety and efficacy evaluation of engineered T cell receptor anti-CD3 bispecific (ImmTAC) moleculesJane Harper, Katherine J Adams, Giovanna Bossi, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|November 18, 2011
Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitorPatrick C May, Robert A Dean, Stephen L Lowe, et al.
JMIR Research Protocols|October 4, 2019
VEROnA Protocol: A Pilot, Open-Label, Single-Arm, Phase 0, Window-of-Opportunity Study of Vandetanib-Eluting Radiopaque Embolic Beads (BTG-002814) in Patients With Resectable Liver MalignanciesLaura Beaton, Henry F J Tregidgo, Sami A Znati, et al.
Journal of Vascular and Interventional Radiology : JVIR|May 8, 2022
Phase 0 Study of Vandetanib-Eluting Radiopaque Embolics as a Preoperative Embolization Treatment in Patients with Resectable Liver MalignanciesLaura Beaton, Henry F J Tregidgo, Sami A Znati, et al.
Plos One|March 28, 2013
CNV analysis in Tourette syndrome implicates large genomic rearrangements in COL8A1 and NRXN1Abhishek Nag, Elena G Bochukova, Barbara Kremeyer, et al.
Journal of Medicinal Chemistry|June 3, 2021
Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE InhibitorDavid L McKinzie, Leonard L Winneroski, Steven J Green, et al.
Genetic Epidemiology|February 11, 2011
Gene-environment interplay in common complex diseases: forging an integrative model—recommendations from an NIH workshopEbony B Bookman, Kimberly McAllister, Elizabeth Gillanders, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|January 23, 2015
The potent BACE1 inhibitor LY2886721 elicits robust central Aβ pharmacodynamic responses in mice, dogs, and humansPatrick C May, Brian A Willis, Stephen L Lowe, et al.
BMC Medicine|January 28, 2024
Integrating multiple lines of evidence to assess the effects of maternal BMI on pregnancy and perinatal outcomesMaria Carolina Borges, Gemma L Clayton, Rachel M Freathy, et al.
Human Molecular Genetics|September 8, 2012
Genetic variation in the 15q25 nicotinic acetylcholine receptor gene cluster (CHRNA5-CHRNA3-CHRNB4) interacts with maternal self-reported smoking status during pregnancy to influence birth weightJessica Tyrrell, Ville Huikari, Jennifer T Christie, et al.
Pageof 52